Philip J Lowe

List of Publications by Year
in descending order

37 papers	2,538 citations	304743 22 h-index	377865 34 g-index
38 all docs	38 docs citations	38 times ranked	2652 citing authors

#	Article	IF	Citations
1	In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes. Journal of Experimental Medicine, 2009, 206, 1029-1036.	8.5	270
2	Pharmacokinetics, pharmacodynamics and safety of <scp>QGE</scp>031 (ligelizumab), a novel high‐affinity anti‐IgE antibody, in atopic subjects. Clinical and Experimental Allergy, 2014, 44, 1371-1385.	2.9	216
3	Omalizumab in Asthma: An Update on Recent Developments. Journal of Allergy and Clinical Immunology: in Practice, 2014, 2, 525-536.e1.	3.8	179
4	A mechanism‐based binding model for the population pharmacokinetics and pharmacodynamics of omalizumab. British Journal of Clinical Pharmacology, 2007, 63, 548-561.	2.4	163
5	Pharmacokinetic and Pharmacodynamic Properties of Canakinumab, a Human Anti-Interleukin-1β Monoclonal Antibody. Clinical Pharmacokinetics, 2012, 51, e1-e18.	3.5	151
6	Relationship between omalizumab pharmacokinetics, IgE pharmacodynamics and symptoms in patients with severe persistent allergic (IgE‐mediated) asthma. British Journal of Clinical Pharmacology, 2009, 68, 61-76.	2.4	146
7	Calcitonin and Insulin in Isobutylcyanoacrylate Nanocapsules: Protection Against Proteases and Effect on Intestinal Absorption in Rats. Journal of Pharmacy and Pharmacology, 2011, 46, 547-552.	2.4	140
8	Physiologically Based Pharmacokinetic Modeling of FTY720 (2-Amino-2[2-(-4-octylphenyl)ethyl]propane-1,3-diol hydrochloride) in Rats After Oral and Intravenous Doses. Drug Metabolism and Disposition, 2006, 34, 1480-1487.	3.3	125
9	Asthma symptom re-emergence after omalizumab withdrawal correlates well with increasing IgE and decreasing pharmacokinetic concentrations. Journal of Allergy and Clinical Immunology, 2009, 123, 107-113.e3.	2.9	123
10	Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. Journal of Allergy and Clinical Immunology, 2016, 138, 1051-1059.	2.9	122
11	Omalizumab decreases IgE production in patients with allergic (IgE‐mediated) asthma; PKPD analysis of a biomarker, total IgE. British Journal of Clinical Pharmacology, 2011, 72, 306-320.	2.4	113
12	Membrane lipid composition and susceptibility to bile salt damage. Biochimica Et Biophysica Acta - Biomembranes, 1980, 599, 294-300.	2.6	99
13	On the Prediction of the Human Response: A Recycled Mechanistic Pharmacokinetic/Pharmacodynamic Approach. Basic and Clinical Pharmacology and Toxicology, 2005, 96, 182-192.	2.5	96
14	On the anticipation of the human dose in first-in-man trials from preclinical and prior clinical information in early drug development. Xenobiotica, 2007, 37, 1331-1354.	1.1	82
15	On Setting the First Dose in Man: Quantitating Biotherapeutic Drug‐Target Binding through Pharmacokinetic and Pharmacodynamic Models. Basic and Clinical Pharmacology and Toxicology, 2010, 106, 195-209.	2.5	73
16	Membrane fluidity and bile salt damage. Biochimica Et Biophysica Acta - Biomembranes, 1981, 640, 55-65.	2.6	62
17	New Approach To Measure Protein Binding Based on a Parallel Artificial Membrane Assay and Human Serum Albumin. Journal of Medicinal Chemistry, 2008, 51, 2009-2017.	6.4	55
18	Population Modeling of Filgrastim PK‐PD in Healthy Adults Following Intravenous and Subcutaneous Administrations. Journal of Clinical Pharmacology, 2010, 50, 101S-112S.	2.0	45

#	ARTICLE	IF	CITATIONS
19	Population Pharmacokinetic and Pharmacodynamic Model–Based Comparability Assessment of a Recombinant Human Epoetin Alfa and the Biosimilar HX575. Journal of Clinical Pharmacology, 2012, 52, 1624-1644.	2.0	34
20	Visualization and Communication of Pharmacometric Models With Berkeley Madonna. CPT: Pharmacometrics and Systems Pharmacology, 2014, 3, 1-20.	2.5	33
21	Revision of omalizumab dosing table for dosing every 4 instead of 2 weeks for specific ranges of bodyweight and baseline IgE. Regulatory Toxicology and Pharmacology, 2015, 71, 68-77.	2.7	31
22	From Target Selection to the Minimum Acceptable Biological Effect Level for Human Study: Use of Mechanism-based PK/PD Modeling to Design Safe and Efficacious Biologics. AAPS Journal, 2011, 13, 169-178.	4.4	26
23	Ligelizumab treatment for severe asthma: learnings from the clinical development programme. Clinical and Translational Immunology, 2021, 10, e1255.	3.8	25
24	Population Pharmacokinetic Modelling of Filgrastim in Healthy Adults following Intravenous and Subcutaneous Administrations. Clinical Pharmacokinetics, 2009, 48, 817-826.	3.5	23
25	Effect of molecular charge on para- and transcellular access of horseradish peroxidase into rat bile. Hepatology, 1989, 9, 866-871.	7.3	19
26	Fluorescence anisotropy from diphenylhexatriene in rat liver plasma membranes. Biochimica Et Biophysica Acta - Biomembranes, 1982, 689, 403-409.	2.6	17
27	Ethnic sensitivity assessment of pharmacokinetics and pharmacodynamics of omalizumab with dosing table expansion. Drug Metabolism and Pharmacokinetics, 2016, 31, 173-184.	2.2	14
28	Integrated pharmacokinetic, pharmacodynamic and immunogenicity profiling of an anti-CCL21 monoclonal antibody in cynomolgus monkeys. MAbs, 2015, 7, 829-837.	5.2	13
29	Applying Physiological and Biochemical Concepts to Optimize Biological Drug Development. Clinical Pharmacology and Therapeutics, 2010, 87, 492-496.	4.7	11
30	Simplification of Complex Physiologically Based Pharmacokinetic Models of Monoclonal Antibodies. AAPS Journal, 2014, 16, 810-842.	4.4	9
31	<title>Uptake of zinc(II)-phthalocyanine by HepG2 cells expressing the low-density lipoprotein receptor: studies with the liposomal formulation CGP55847</title>. , 1994, , .		8
32	Membrane damage caused by bile salts. Biochemical Society Transactions, 1980, 8, 126-127.	3.4	6
33	BREAKDOWN OF HEPATIC TIGHT JUNCTIONS DURING REOXYGENATION INJURY. Transplantation, 1992, 53, 1211-1214.	1.0	6
34	Two Case Studies on How Study Designs Can Be Made More Informative Using Modeling and Simulation Approaches. Clinical Pharmacology and Therapeutics, 2017, 102, 908-911.	4.7	1
35	Improving priors for human monoclonal antibody linear pharmacokinetic parameters by using half-lives from non-human primates. Journal of Pharmacokinetics and Pharmacodynamics, 2021, 48, 295-303.	1.8	1
36	Output of proteins in bile by isolated perfused rat livers. Biochemical Society Transactions, 1982, 10, 222-222.	3.4	0

#	Article	IF	Citations
37	Utility of food pellets containing 1-aminobenzotriazole for longer term *in vivo* inhibition of cytochrome P450 in mice. Xenobiotica, 2019, 49, 13-21.	1.1	0